Plain-English translation of NCT06213038 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing SKG0106, a new medication that is injected directly into the eye to treat wet age-related macular degeneration (a disease that damages central vision in older adults). The trial will evaluate whether the medication is safe and whether it works effectively by monitoring vision and eye health. Researchers will also test three different dose levels to find the right amount.
Current treatments for wet age-related macular degeneration require repeated injections over time, and some patients eventually stop responding to them. This trial is testing whether this new treatment could offer a longer-lasting option with just a single injection.
You likely qualify if…
You likely don't qualify if…
You would receive a single injection of the medication directly into your eye during a baseline visit. The study will enroll 12 participants total and test three different dose levels to understand safety and effectiveness. You would then return for follow-up visits to have your vision checked, your eye examined, and blood tests performed to see how your body responds to the treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China